Inventor · disambiguated record
Nels Eric Pederson
Also filed as: PEDERSON NELS · PEDERSON NELS E · PEDERSON NELS ERIC
21 granted patents·9 pending applications·62 citations·filing 2004–2025
93Inventor score
Files withBLUEFIN BIOMEDICINE INC18KINIKSA PHARMACEUTICALS LTD7BIOGEN MA INC3BIOGEN IDEC INC1KHETAN ANURAG1
Top patents by PatentIndex Score
30 records- 0193US12138314B2Anti-CUB domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 12, 2024·1 cites·8 claims
- 0293US12138313B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 12, 2024·1 cites·8 claims
- 0389US11702481B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2017·Granted Jul 18, 2023·3 cites·19 claims
- 0489US11312769B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Apr 26, 2022·4 cites·14 claims
- 0589US2025230250A1Oncostatin m receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2024·Application pending·0 cites
- 0688US11981732B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted May 14, 2024·1 cites·19 claims
- 0788US11634486B2Anti-SEZ6L2 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2017·Granted Apr 25, 2023·3 cites·4 claims
- 0888US9593163B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2016·Granted Mar 14, 2017·5 cites·16 claims
- 0987US7598059B2Neublastin expression constructsBIOGEN IDEC INC·Filed 2004·Granted Oct 6, 2009·19 cites·18 claims
- 1084US9096879B2Method of supplementing culture media to prevent undesirable amino acid substitutionsKHETAN ANURAG·Filed 2009·Granted Aug 4, 2015·18 cites·17 claims
- 1183US12491256B2Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereofBLUEFIN BIOMEDICINE INC·Filed 2023·Granted Dec 9, 2025·0 cites·18 claims
- 1282US12473358B2Anti-TMEFF1 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2024·Granted Nov 18, 2025·0 cites·19 claims
- 1382US11434303B2Anti-LY6H antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Sep 6, 2022·1 cites·12 claims
- 1481US9663571B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2014·Granted May 30, 2017·3 cites·16 claims
- 1579US2025092132A1Anti-ilt3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2024·Application pending·0 cites
- 1678US12122837B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2021·Granted Oct 22, 2024·0 cites·28 claims
- 1778US10421813B2Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2017·Granted Sep 24, 2019·1 cites·12 claims
- 1877US9738721B1Oncostatin M receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2017·Granted Aug 22, 2017·1 cites·16 claims
- 1977US2025368747A1Anti-il1rap antibodies and compositionsBLUEFIN BIOMEDICINE INC·Filed 2025·Application pending·0 cites
- 2076US12296006B2Anti-LY6H antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted May 13, 2025·0 cites·14 claims
- 2176US11267886B2Anti-ILT3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Mar 8, 2022·1 cites·13 claims
- 2275US2023331839A1Anti-sez6l2 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2023·Application pending·0 cites
- 2373US12110326B2Anti-ILT3 antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2022·Granted Oct 8, 2024·0 cites·22 claims
- 2473US2025319180A1Anti-ly6h antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2025·Application pending·0 cites
- 2569US12350347B2Nucleic acids encoding anti-IL1RAP antibodies and their usesBLUEFIN BIOMEDICINE INC·Filed 2021·Granted Jul 8, 2025·0 cites·13 claims
- 2668US2019359724A1Oncostatin m receptor antigen binding proteinsKINIKSA PHARMACEUTICALS LTD·Filed 2019·Application pending·0 cites
- 2759US11248054B2Anti-IL1RAP antibodies and antibody drug conjugatesBLUEFIN BIOMEDICINE INC·Filed 2018·Granted Feb 15, 2022·0 cites·8 claims
- 2852US2022089704A1Humanized and stabilized fc5 variants for enhancement of blood brain barrier transportBIOGEN MA INC·Filed 2019·Application pending·0 cites
- 2939US2020270335A1Dkk2 cysteine rich domain 2 containing proteins and uses thereofBIOGEN MA INC·Filed 2016·Application pending·0 cites
- 3031US2017362324A1Humanized anti-alpha v beta 5 antibodies and uses thereofBIOGEN MA INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →